Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in COVID-19 to prevent respiratory failure in community care (AVID-CC)
2020-003628-18Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of adalimumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Oxford. Primary endpoint: Progression to severe or critical illness or death at 28 days. Status: unknown.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003628-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003628-18.